

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087035 A1(51) International Patent Classification⁷: C07C 225/28,
221/00, A61P 25/28Maurizio [IT/IT]; Via Emilia Ponente, 250/2, I-40132
Bologna (IT).

(21) International Application Number: PCT/IT03/00227

(74) Agents: JORIO, Paolo et al.; c/o Studio Torta S.r.l., Via
Viotti, 9, I-10121 Torino (IT).

(22) International Filing Date: 11 April 2003 (11.04.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: Italian


(26) Publication Language: English

(30) Priority Data:
BO2002A000198 12 April 2002 (12.04.2002) IT(71) Applicant (for all designated States except US): ALMA
MATER STUDIORUM [IT/IT]; Universita'Di Bologna,
Via Zamboni, 33, I-40126 Bologna (IT).(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:(75) Inventors/Applicants (for US only): ANDRISANO,
Vincenza [IT/IT]; Via Toscanini, 8, I-40136 Bologna (IT).
BARTOLINI, Manuela [IT/IT]; Via Monte Coco, 14,
I-61037 Mondolfo (IT). BOLOGNESI, Maria, Laura
[IT/IT]; Via Cartoleria, 20, I-40124 Bologna (IT). CAV-
ALLI, Andrea [IT/IT]; Via Jussi, 11/A, I-40128 San
Lazzaro Di Savena (IT). MELCHIORRE, Carlo [IT/IT];
Via Faenza, 7, I-40139 Bologna (IT). RECANATINI,

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.A1 (54) Title: 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR(57) Abstract: 2,5-bis-di-
amine-[1,4]benzoquinonic derivatives,
having a general formula (I) have proved
useful for the treatment of Alzheimer's
disease; a method for preparing them
and intermediates used in said method
are also described. Formula (I).

WO 03/087035

- 1 -

2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF
ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES
THEREFOR

5

TECHNICAL FIELD

The present invention concerns new 2,5-bis-diamine-[1,4]benzoquinonic derivatives. The invention also concerns a use of these compounds as medicaments, 10 in particular for the treatment of Alzheimer's disease, their use for the creation of pharmaceutical preparations for the treatment of Alzheimer's disease, pharmaceutical which contain them, methods for preparing them and intermediates of said methods.

The present invention also concerns a use of 2,5-bis-diamine-[1,4] benzoquinonic derivatives for the production of a pharmaceutical preparation having protein β -amyloid (A β) anti-aggregating properties and for the treatment of 15 degenerative pathologies of the nervous system.

BACKGROUND ART

Alzheimer's disease (AD) is a neurodegenerative syndrome generally linked 20 with ageing which leads patients to a progressive deterioration of their cognitive and behavioural functions. The great majority of cases of AD has causes that are currently substantially unknown. Also for this reason, today there are still no therapeutic treatments able to halt the progression of the disease, even though some drugs have recently been put on the market, aimed especially at the control of the 25 cognitive symptoms. These drugs - Tacrine (Cognex®), Donepezil (Aricept®) and Rivastigmine (Exelon®) – share the same action mechanism, which consists of the inhibition of acetylcholinesterase (AChE).

The therapeutic approach based on the inhibition of AChE is founded on the observation that the neuron degeneration associated with AD occurs prevalently in cerebral areas innervated by cholinergic neurons. The loss of cholinergic activity in those areas (cortex and hippocampus, especially) would be responsible for the cognitive dysfunctions typical of AD. AChE is the enzyme that inactivates the cholinergic neurotransmitter acetylcholine (ACh), and the hypothesis has been expressed that the block of the functioning of this enzyme could prolong the stimulation of the receptor, strengthening cholinergic transmission. The known drugs mentioned above derive from the application of this hypothesis called "cholinergic hypothesis" (Bartus, R. T.; Dean, R. L., 3rd; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, Vol. 217, p. 408-414). However, one cannot overlook the limits of this approach which consist substantially in the lack of action on the progression of the disease and in the presence of undesired collateral effects, which limit dosage and can induce the patient to interrupt taking one of the drugs mentioned above.

Although the strengthening of cholinergic transmission through the inhibition of AchE is a useful approach to the treatment of cognitive symptoms associated with AD, it has recently been proposed that the loss of neurons and the consequent appearance of cognitive symptoms are the result of a cascade of biochemical events linked with the overproduction of β -amyloid protein in certain cerebral areas. This protein tends to aggregate, forming extracellular deposits, which give rise to the typical lesions found in the brain of AD patients: senile plaques. The presence of these plaques produces responses of an inflammatory and oxidative type in the surrounding tissue, triggering a chain of toxic events, including an increase of the phosphorylation of tau protein, due to the activation of enzymes of inflammation and to the formation of oxygenated radical species. The progression of neurodegeneration derives from the impossibility of controlling the spread of these

harmful effects. It is therefore necessary to discover pharmacological instruments that are able to act as far upstream as possible in the neurodegenerative cascade.

Moreover, it is important to stress that there are other pathologies besides Alzheimer's disease characterised by deposits of A β . These pathologies include:

5 Down's syndrome, hereditary cerebral haemorrhage associated with amyloidosis of the "Dutch type", amyloidosis associated with chronic inflammations, amyloidosis associated with multiple myelomas and other dyscrasias of the B lymphoid haematic cells, amyloidosis associated with diabetes type II, amyloidosis associated with diseases deriving from prions such as Creutzfeldt-Jakob's disease, the
10 Gertsmann-Straussler syndrome, Kuru and scrapie in sheep (WO 02/00603).


From the above it is clear that there is still a considerable need to make medicaments available for the treatment of AD and for the treatment of pathologies characterised by deposits of A β .

DISCLOSURE OF INVENTION

15 The aim of the invention is therefore to supply substances that can be used to advantage in the treatment of AD, of all the other syndromes connected to the accumulation of A β , in particular preventing said accumulation, and of the degenerative pathologies of the nervous system.

According to the present invention a 2,5-bis-diamine-[1,4]benzoquinonic
20 derivative is realised having a general formula (I):

(I)



in which R₁ represents a substituent chosen from the group consisting of:

- a hydrogen,

- 4 -

- a saturated or unsaturated, linear or ramified alkylic group of from one to five carbon atoms, and

- a substituent having an attractor electron inductive effect;

R₂ and R₃, each independently of the other, represent a hydrogen or a 5 saturated or unsaturated, linear or ramified alkylic group presenting from one to five carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group presenting from one to five carbon atoms,
- OMe, and
- SMe;

X represents a radical chosen from the group consisting of:

- -HC=CH-,
- -HC=N-,
- -S-,
- -O-, and
- -NH-;

T represents a saturated or unsaturated, linear or ramified alkylic group 20 presenting from one to four carbon atoms;

Z represents a saturated or unsaturated, linear or ramified alkylic group presenting from two to thirteen carbon atoms; preferably R₁ represents a substituent chosen from the group consisting of:

- a hydrogen,
- a substituent having an attractor electron inductive effect.

Preferably, in the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I), R₁ represents a substituent chosen from the group consisting

of:

- a hydrogen,
- a halogen,
- NO₂, and
- 5 - MeO;

R₂ and R₃, each independently of the other, represent a hydrogen or a saturated or unsaturated, linear or ramified alkylic group presenting from one to four carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

10

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group presenting from one to five carbon atoms,

X represents a radical chosen from the group consisting of:

15

- -HC=CH-,
- -HC=N-,
- -S-,
- -O-, and
- -NH-;

T represents a saturated or unsaturated, linear alkyl presenting from one to
20 three carbon atoms;

Z represents a saturated or unsaturated, linear alkyl presenting from two to twelve carbon atoms.

Preferably, in the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I), R₁ represent a substituent chosen from the group consisting of:

25

- a hydrogen,
- a halogen,
- MeO;

- 6 -

R₂ and R₃, each independently of the other, represent a hydrogen or a saturated or unsaturated, linear alkylic group presenting from one to two carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

5 - hydrogen,
 - a saturated linear or ramified alkylic group, presenting from one to four carbon atoms,

X represents the radical -HC=CH- or -O-;

T represents the radical -CH₂-; and

10 Z represents a saturated linear alkyl presenting from two to seven carbon atoms.

According to particularly preferred embodiments, in the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) R₁ represents a substituent chosen from the group consisting of:

15 - a hydrogen,
 - a halogen,
 - MeO;

R₂ represents a hydrogen or a saturated linear alkylic group, presenting from one to two carbon atoms; R₃ represents a hydrogen; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

 - hydrogen,
 - a saturated linear alkylic group, presenting from one to two carbon atoms,
 - a ramified alkylic group presenting from three to four carbon atoms,

X represents the radical -HC=CH- or -O-;

25 T represents the radical -CH₂-; and

Z represents a saturated linear alkyl presenting from two to seven carbon atoms.

Particularly preferred are the embodiments according to which in the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I), R₁ is in position 2 with respect to T. Preferred are also the embodiments according to which Z represents a saturated linear alkyl presenting from two to seven carbon atoms and 5 the embodiments in which X represents the radical -CH=CH-.

Even more preferred are the embodiments according to which the 2,5-bis-diamine-[1,4]benzoquinonic derivative is chosen from the group consisting of the 2,5-bis-diamine-[1,4]benzoquinonic derivatives illustrated in the enclosed examples.

10 The 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) can exist in different stereoisomer forms such as enantiomer or diastereoisomer. The invention concerns both enantiomers and diastereoisomers or their mixtures. These mixtures can be separated by means of known methods into their stereoisomerically uniform components.

15 According to the present invention, a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) is supplied for use as a medicament.

According to the present invention, a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) is supplied for the treatment of Alzheimer's disease in mammals.


20 According to the present invention, a method is supplied for the treatment of Alzheimer's disease in a mamma, comprising the administration to said mammal of an efficacious quantity of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I).

According to the present invention, a pharmaceutical preparation is supplied, 25 characterised in that it comprises a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) or one of its pharmaceutically acceptable salts and a pharmaceutically acceptable excipient and/or diluent.

According to the present invention, a use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) is supplied for the production of a pharmaceutical preparation for the treatment of Alzheimer's disease in mammals.

5 According to the present invention, a method is supplied for preparing a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula 2 (I); the method comprises a substitution phase, in which on a p-benzoquinone having a general formula (VIII):

10



(VIII)

a substitution is carried out with a compound (VII):



(VII)

15 in order to obtain the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I).

According to the present invention, compounds are also supplied according to claims from 8 to 20.

According to a further aspect of the present invention, the use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) is supplied for the production of a pharmaceutical preparation for the treatment of pathologies characterised by deposits of β -amyloid protein ($A\beta$) in mammals.

According to the present invention, a method is supplied for the treatment of the disease of a pathology characterised by deposits of β -amyloid protein ($A\beta$) in a

mammal, comprising the administration to said mammal of an efficacious quantity of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I).

According to a further aspect of the present invention, the use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I), is supplied for
5 the production of a pharmaceutical preparation for the treatment of degenerative pathologies of the nervous system in mammals.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described with reference to the enclosed drawings, which illustrate an example of an embodiment without limitation, in which:

10 figure 1 illustrates an experimental graph of Lineweaver-Burk;

figure 2 illustrates an experimental graph depicting the gradient function of the lines of the graph in figure 1 with relation to the concentrations of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I); and

15 figure 3 illustrates the intensity of fluorescence (expressed in fluorescence units) of thioflavine complexed with fibrils of A β in the presence of variable concentrations of a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

20 figures 4A, 4B and 4C illustrate coronal sections of the basal forebrain of, respectively, non transgenic mice, transgenic mice (AD11) treated with a saline solution and transgenic mice (AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

figure 5 illustrates the total number of cholinergic neurons in the basal forebrain;

25 figure 6 illustrates the total number of cholinergic neurons in Meynert's basal nucleus;

figures 7A, 7B and 7C illustrate the depositions of APP in the cerebral vessels of, respectively, non transgenic mice, transgenic mice (AD11) treated with

- 10 -

a saline solution, transgenic mice(AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

5 figures 8A, 8B, 8C illustrate coronal sections of the entorhinal cortex of, respectively, non transgenic mice, transgenic mice (AD11) treated with a saline solution, transgenic mice(AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

10 figures 9A, 9B, 9C illustrate coronal sections of the basal forebrain of, respectively, non transgenic mice, transgenic mice (AD11) and transgenic mice (AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

figures 10A, 10B, 10C illustrate coronal sections of the entorhinal cortex of, respectively, non transgenic mice, transgenic mice (AD11), transgenic mice (AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

15 figures 11A, 11B, 11C illustrate sections of the hippocampus of, respectively, non transgenic mice (AD11), transgenic mice (AD11) and transgenic mice (AD11) treated with a 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I);

20 figures 12, 13, 14 and 21 illustrate discrimination indices found in experiment;

figures 15 and 16 illustrate the total number of cholinergic neurons found in the basal forebrain;


figures 17 and 18 illustrate the number of neurons that express phospho-tau in the entorhinal cortex;

25 figure 19 illustrates the extracellular charge of APP; and

figure 20 illustrate the number of cells accumulated by β -amyloid.


BEST MODE FOR CARRYING OUT THE INVENTION

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives represented by the general formula (I) described above can be prepared, for example, starting from a protected (amino-alkyl)-carbamic acid having a general formula (II):




(II),

5 in which D represents a Benzyl (Bn) or another stable protective group in a basic environment. A compound having a general formula (III) is added to the (amino-alkyl)-carbamic acid (II)



(III),

in which E represents =O, -Cl, -Br or -I, so as to obtain an intermediate
10 compound having a general formula (IV):



(IV)

with the condition that, where E represents =O, the reaction occurs in the presence of a suitable reducing agent.

Preferably said reducing agent is NaBH₄, the reaction is realised in a protic
15 organic solvent, for example ethanol, at a temperature between 15° and 35° C, in particular at substantially 25° C, in the presence of molecular sieves (in particular of 4 Å).


At this point, the compound (IV) has been made to react in the presence of a base with a compound having a general formula (V):

(V)

 $(R_2)_f A,$

in which A is an attractor electron group and f is 1 or 2 so as to obtain an intermediate compound having a general formula (VI):

5 (VI)



Preferably the compound (V) is $(R_2)_2 SO_4$, in particular $Et_2 SO_4$, and the reaction is carried out in an inert organic solvent, which does not change in the reaction conditions, and at a temperature between 80° C and 170° C, in particular at substantially 111° C.

10 The solvents that can be used include: ethers, such as diethyl ether or tetrahydrofuran; halogenated hydrocarbons, such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethylene or trichloroethylene; hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or petroleum ether, nitromethane, 15 dimethylformamide, acetone or acetonitrile. It is also possible to use mixtures of the solvents mentioned. Toluene is the solvent particularly preferred for this reaction.

At this point, the carbamic function is hydrolysed in the compound (VI) in order to obtain a compound having a general formula (VII):

20 (VII)




Hydrolysis preferably takes place in an acid environment and the solvent used is acetic acid. According to a particularly preferred embodiment, HBr is used

for hydrolysis.

At this point on a p-benzoquinone having a general formula (VIII):

(VIII)



a substitution is made with the compound (VII) in order to obtain the 2,5-bis-
5 diamine-[1,4]benzoquinonic derivative having a general formula (I).

Surprisingly, the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) has shown a relatively high activity for the treatment of Alzheimer's disease (AD) in mammals.

Moreover, surprisingly, the 2,5-bis-diamine-[1,4]benzoquinonic derivative
10 having a general formula (I) has presented a relatively very high activity of inhibition of the enzyme acetylcholinesterase (AChE).

In particular, the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) has presented an activity of AChE inhibition relatively much higher than the activity of inhibition that the same 2,5-bis-diamine-
15 [1,4]benzoquinonic derivative (I) presented with relation to the enzyme butyrylcholine esterase (BuChE).

On this point, it is important to stress that the capacity of the 2,5-bis-diamine-[1,4]benzoquinonic derivative (I) to bind preferentially with AChE rather than with BuChE, avoids the 2,5-bis-diamine-[1,4]benzoquinonic derivative (I) being
20 distracted from its primary objective (that is AChE). In the past it has been supposed that BuChE acts as an enzymatic system protecting AChE against false substrata.

Moreover, the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a

general formula (I) surprisingly presents an inhibiting activity with regard to the aggregation of A β induced by AChE.

It is important to stress that the quinonic functionality presents a protective antioxidant activity with respect to the oxidative stress due to the accumulation of
5 A β . The inhibiting activity with regard to the aggregation of A β and the antioxidant activity, surprisingly, combine synergically to substantially improve the conditions of patients affected by pathologies characterised by deposits of A β .

In particular, it is important to stress that the relatively very high AChE inhibiting activity, the relatively low BuChE inhibiting activity, the inhibiting activity with regard to the aggregation of A β and the antioxidant activity,
10 surprisingly, combine synergically to substantially improve the conditions of patients affected by AD.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) or their pharmaceutically acceptable salts, can be administered as pure compounds,
15 however they are preferably presented in the form of a pharmaceutical formula. Non limiting examples of suitable pharmaceutical formulae are listed below.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can be formulated for oral, parenteral or rectal administration or in forms suited for administration by inhalation or insufflation (both by mouth and by nose). Formulae for oral or
20 parenteral administration are preferred.

For oral administration, the pharmaceutical preparations can be, for example, in the form of tablets or capsules prepared using known methods with excipients acceptable from a pharmaceutical point of view as binding agents (for example pre-gelatised corn starch, polyvinylpyrrolidone or methylcellulose); fillers (for example lactose, microcrystalline cellulose or calcium hydrogen phosphate); additives (for example magnesium stearate, talc, silica); disintegrants (for example potato starch);
25 and/or lubricating agents (for example sodium lauryl sulphate). The tablets can be

coated with known methods. Liquid preparations for oral administration may have the form, for example, of syrupy solutions or suspensions, or they can be in the form of a dry product which can be dissolved in water or in another liquid before use. These preparations can be prepared in known ways with pharmaceutically acceptable additives such as suspending agents (for example sorbitol, cellulose derivatives, edible hydrogenated fats); emulsifying agents (for example lecithin or acacia); non aqueous liquids (for example almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and/or preservatives (for example methyl or propylhydroxybenzoates, sorbic acid or ascorbic acid). The preparations can also contain, in appropriate cases, buffering salts, colouring, aromatic and/or sweetening agents.

Preparations for oral administration can be formulated in a known way, so as to give a controlled release of the active compound.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can be formulated, in a known way, for parenteral administration by injection or continuous administration. Formulae for injection may be in the form of single doses, for example in ampoules or multidose containers containing preservatives. The composition may be in the form of a suspension, in aqueous or oily liquids, and it may contain formulation elements such as dispersing and stabilising agents. Alternatively, the active compound may be in powder form to be dissolved immediately before use in a suitable liquid, for example sterilised water.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can be formulated for rectal administration as suppositories or enteroclysis, for example containing excipients for suppositories of a known type such as cocoa butter or other fats.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can also be formulated, in a known way, as compositions with prolonged release. These compositions with prolonged release can be administered by means of an implant (for example subcutaneous, or intramuscular) or by means of an intramuscular

injection. So, for example, the 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can be formulated with suitable polymeric or hydrophobic materials (for example an emulsion or an oil) or resins with ionic exchange, or relatively poorly soluble derivatives, such as relatively poorly soluble salts.

5 For intranasal administration, the 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) can be formulated for administration by means of a (known) device, for example in powder form with a suitable carriers.


The dosages of the 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I) will depend on the age and conditions of the patient, so the precise dosage must be 10 decided from time to time by the doctor. The dosage will also depend on the means of administration and on the particular compound selected. Usable doses may be for example between 0.1 mg/Kg and 400 mg/Kg with respect to body weight per day.

The 2,5-bis-diamine-[1,4]benzoquinonic derivatives (I), can be administered 15 in combination with one or more suitable therapeutic agents and formulated in every known usable way.

Further characteristics of the present invention will appear more clearly from the following description which refers to embodiments taken purely as examples and without limitation.

20 **Example 1**

This example describes the synthesis of the acid [3-(2-methoxy-benzylamino)-propyl]-carbamic benzyl ester (IX) having the formula:




To a solution of (3-amino-propyl)-carbamic benzyl ester acid (1.04 g, 5 mmol) in 50 ml of ethanol containing molecular sieves (4 Å), 2-

- 17 -

methoxybenzaldehyde was added (0.75 g, 5.5 mmol). The mixture was left in agitation at environment temperature (e.t.) for 20 min, then NaBH₄ was added when cold (0.2 g, 5 mmol). It was left to react for 6h, it was acidified cautiously with HCl 2N, the sieves were filtered and the solvents were evaporated; the residue was taken again with H₂O and extracted with diethyl ether (3 x 10 ml). The aqueous solution was then basified with NaOH 40% and extracted with CHCl₃ (4 x 20 ml). The anhydriified and evaporated organic extracts gave 1.5 g of the compound IX as pure transparent oil on TLC (eluant: CHCl₃/EtOH/NH₄OH 9.0:1.0:0.1). Yield 90%; ¹H NMR (free base; CDCl₃) δ: 1.61-1.79 (m, 2H + 1H exchangeable with D₂O), 2.70 (t, 2H), 3.32 (q, 2H), 3.78 (s, 2H), 3.84 (s, 3H), 5.11 (s, 2H), 5.73 (s enlarged, 1H exchangeable with D₂O), 6.84-6.95 (m, 2H), 7.19-7.40 (m, 7H).

Example 2

This example describes the synthesis of the acid {3-[ethyl-(2-methoxy-benzyl)-amino]-propyl}-carbamic benzyl ester (X) having the formula:




To a solution of [3-(2-methoxy-benzylamino)-propyl]-carbamic benzyl ester acid (1.4 g; 4.3 mmol) in 70 ml of toluene diethyl sulphate was added (1.24 ml; 9.5 mmol) and heated by reflux for 24h. The reaction mixture was cooled at e.t. and beaten with conc. NaOH (50 ml). The organic phase was separated, which after anhydriification and evaporation gave a crude material which was purified by flash chromatography. Eluting with CH₂Cl₂/ether of petroleum/MeOH/NH₄OH 4.6:5.0:0.4:0.04 obtained 1.4 g of the compound X as pure transparent oil on TLC (eluant: CHCl₃/MeOH/NH₄OH 9.5:0.5:0.05). Yield 91%; ¹H NMR (free base;

CDCl_3) δ : 1.08 (t, 3H), 1.61-1.79 (m, 2H), 2.53-2.75 (m, 4H), 3.32 (q, 2H), 3.78 (s, 2H), 3.84 (s, 3H), 5.11 (s, 2H), 5.73 (s enlarged, 1H exchangeable with D_2O), 6.84-6.95 (m, 2H), 7.19-7.40 (m, 7H).

Example 3

5 This example describes the synthesis of N^1 -ethyl- N^1 -(2-methoxy-benzyl)-propan-1,3-diamine (XI) having the formula:




To a solution of {3-[ethyl-(2-methoxy-benzyl)-amino]-propyl}-carbamic benzyl ester acid (1.4 g; 3.9 mmol) in 15 ml of glacial CH_3COOH , 3.5 ml of a 33% solution of HBr in CH_3COOH was added cautiously. It was left in agitation for 2h, 10 then the hydrobromate was precipitated with 100 ml of diethyl ether. The white solid formed was solubilised in H_2O , basified with NaOH 2N and extracted with CHCl_3 (5x 20 ml). The anhydriified organic phase was evaporated in a vacuum to give 0.87 g of the compound XI as pure transparent oil on TLC (eluant $\text{CHCl}_3/\text{MeOH}/\text{NH}_4\text{OH}$ 9.0:1.0:0.1); quantity yield; $^1\text{H NMR}$ (free base; CDCl_3) δ :

15 1.07 (t, 3H), 1.50 (s enlarged, 2H exchangeable with D_2O), 1.57-1.71 (m, 2H), 2.55 (q, 4H), 2.73 (t, 2H), 3.60 (s, 2H), 3.84 (s, 3H), 6.83-6.99 (m, 2H), 7.19-7.44 (m, 2H).

Example 4

This example describes the synthesis of 2,5-Bis-{3-[ethyl-(2-methoxy-benzyl)-amino]-propylamino}-[1,4]benzoquinone (XII) having the formula:




To a solution of p-benzoquinone (0.1 g; 0.92 mmol) in 70 ml of MeOH was

added when cold N¹-ethyl-N¹-(2-methoxy-benzyl)-propan-1,3-diamine (0.45 g; 2.0 mmol). The reaction mixture was agitated at e.t. and out of the light for 6h, the was evaporated in a vacuum to give a crude material which was purified by flash chromatography. Eluting with CH₂Cl₂/MeOH/NH₄OH 9.75:0.25:0.025 obtained 5 0.23 g of the compound XII as a pure red solid on TLC (eluant: CHCl₃/MeOH/NH₄OH 9.5:0.5:0.05). Yield 45%; ¹H NMR (free base; CDCl₃) δ: 1.11 (t, 6H), 1.72-1.85 (m, 4H), 2.56 (q, 8H), 3.18 (q, 4H), 3.62 (s, 4H), 3.82 (s, 6H), 5.26 (s, 2H), 6.83-6.95 (m, 4H), 7.19-7.43 (m, 4H + 2H exchangeable with D₂O); EI-MS: m/z = 548 (M⁺).

10 Example 5


This example describes the synthesis of the acid [6-(2-methoxy-benzylamine-hexyl]-carbamic benzyl ester (XIII):



The compound XIII was obtained as a transparent oil from the acid (6-amino-hexyl)-carbamic benzyl ester (2.50 g, 10 mmol) following the same procedure described in example 1; yield 81%; ¹H NMR (free base; CDCl₃) δ: 1.22-1.38 (m, 4H), 1.41-1.57 (m, 4H), 1.65 (s enlarged, 1H exchangeable with D₂O), 2.58 (t, 2H), 3.18 (q, 2H), 3.77 (s, 2H), 3.84 (s, 3H), 4.76 (s enlarged, 1H exchangeable with D₂O), 5.09 (s, 2H), 6.82-6.93 (m, 2H), 7.20-7.40 (m, 7H).

Example 6

20 This example describes the synthesis of the acid {6-[ethyl-(2-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (XIV):




The compound XIV was obtained as a transparent oil from the acid [6-(2-

- 20 -

methoxy-benzylamino)-hexyl]-carbamic benzyl ester (2.91 g, 7.85 mmol) following the same procedure described in example 2. Yield 76%; ¹H NMR (free base; CDCl₃) δ: 1.05 (t, 3H), 1.21-1.32 (m, 4H), 1.40-1.57 (m, 4H), 2.41-2.59 (m, 4H), 3.16 (q, 2H), 3.60 (s, 2H), 3.80 (s, 3H), 4.73 (s enlarged, 1H exchangeable with D₂O), 5.08 (s, 2H), 6.82-6.94 (m, 2H), 7.18-7.42 (m, 7H).

Example 7


This example describes the synthesis of N¹-ethyl-N¹-(2-methoxy-benzyl)-hexan-1,6-diamine (XV):



The compound XV was obtained as a transparent oil from the acid {6-[ethyl-(2-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (2.31 g; 6.01 mmol) following the same procedure described in example 3. Yield 98%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 3H), 1.12-1.48 (m, 8H +2H exchangeable with D₂O), 2.41-2.53 (m, 4H), 2.65 (t, 2H), 3.57 (s, 2H), 3.81 (s, 3H), 6.82-6.94 (m, 2H), 7.16-7.42 (m, 2H).

Example 8

This example describes the synthesis of 2,5-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XVI):




The compound XVI was obtained as a red solid from N¹-ethyl-N¹-(2-methoxy-benzyl)-hexan-1,6-diamine (1.05 g; 4 mmol) and p-benzoquinone (0.2 g; 1.84 mmol) following the same procedure described in example 4. Yield 17%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 6H), 1.14-1.38 (m, 8H), 1.43-1.53 (m, 4H),

1.57-1.65 (m, 4H), 2.41-2.56 (m, 8H), 3.10 (q, 4H), 3.57 (s, 4H), 3.81 (s, 6H), 5.28 (s, 2H), 6.59 (t enlarged, 2H exchangeable with D₂O), 6.83-6.95 (m, 4H), 7.21 (t, 2H), 7.39 (d, 2H). EI-MS: m/z = 632 (M⁺).

Example 9


5 This example describes the synthesis of 2,5-Bis-[6-(benzyl-ethyl-amino)-hexylamino]-[1,4]benzoquinone (XVII):



The compound XVII was obtained as a red solid from N¹-ethyl-N¹-benzyl-hexan-1,6-diamine (0.47 g; 2 mmol) and p-benzoquinone (0.1 g; 0.92 mmol) following the same procedure described in example 8. Yield 20%; ¹H NMR (free base; CDCl₃) δ: 1.05 (t, 6H), 1.14-1.39 (m, 8H), 1.43-1.53 (m, 4H), 1.58-1.65 (m, 4H), 2.41-2.56 (m, 8H), 3.10 (q, 4H), 3.71 (s, 4H), 5.28 (s, 2H), 6.44 (t enlarged, 2H exchangeable with D₂O), 7.10-7.24 (m, 10H). EI-MS: m/z = 572 (M⁺). N¹-ethyl-N¹-benzyl-hexan-1,6-diamine was obtained with procedures similar to those described in examples 1-4 using corresponding starting compounds.

15 **Example 10**

This example describes the synthesis of 2,5-Bis-{6-[ethyl-(2-chloro-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XVIII):




The compound XVIII was obtained as a red solid from N¹-ethyl-N¹-(2-chloro-benzyl)-hexan-1,6-diamine (0.54 g; 2 mmol) and p-benzoquinone (0.1 g; 0.92 mmol) following the same procedure described in example 8. Yield 15%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 6H), 1.10-1.35 (m, 8H), 1.43-1.53 (m, 4H),

- 22 -

1.57-1.65 (m, 4H), 2.41-2.56 (m, 8H), 3.08 (q, 4H), 3.46 (s, 4H), 5.28 (s, 2H), 6.59 (t enlarged, 2H exchangeable with D₂O), 7.05-7.23 (m, 6H), 7.45 (d, 2H). EI-MS: m/z = 641 (M⁺). N¹-ethyl-N¹-(2-chloro-benzyl)-hexan-1,6-diamine was obtained with procedures similar to those described in examples 1-4 using corresponding starting compounds.

Example 11


This example describes the synthesis of 2,5-Di-tert-butyl-3,6-bis-{3-[ethyl-(2-methoxy-benzyl)-amino]-propylamino}-[1,4]benzoquinone (XIX):



The compound XIX was obtained as a fuchsia coloured solid from the compound having the formula XI (90 mg; 0.40 mmol) and 2,5-di-tert-butyl-[1,4]benzoquinone (40 mg; 0.18 mmol), following the same procedure described in example 8. Yield 10%; ¹H NMR (free base; CDCl₃) δ: 1.09 (t, 6H), 1.15 (s, 9H), 1.27 (s, 9H), 1.70-1.83 (m, 4H), 2.52-2.64 (m, 8H), 3.15 (s, 3H), 3.54-3.71 (m, 4H), 3.83 (s, 3H), 6.81-6.96 (m, 4H), 7.18-7.44 (m, 4H). EI-MS: m/z = 660 (M⁺).

Example 12

This example describes the synthesis of the acid [6-benzylamino-hexyl]-carbamic benzyl ester (XX) having the formula:




The compound XX was obtained as a transparent oil from the acid (6-amino-hexyl)-carbamic benzyl ester (4.00 g, 16 mmol) following the same procedure described in example 1. Quantity yield; ¹H NMR (free base; CDCl₃) δ: 1.22-1.57 (m, 6H + 1H exchangeable with D₂O), 1.78-1.97 (m, 2H), 2.75 (t, 2H), 3.18 (q, 2H), 4.05 (s, 2H), 5.01 (t enlarged, 1H exchangeable with D₂O), 5.15 (s, 2H), 7.30-

7,45 (m, 8H), 7,57-7,65 (m, 2H).

Example 13


This example describes the synthesis of the acid [6-(ethyl-benzyl-amino)-hexyl]-carbamic benzyl ester (XXI):



The compound XXI was obtained as a transparent oil from the acid [6-benzylamino-hexyl]-carbamic benzyl ester (5.00 g, 14 mmol) following the same procedure described in example 2. Yield 30%; ^1H NMR (free base; CDCl_3) δ : 1,10 (t, 3H), 1,22-1,40 (m, 4H), 2,40-2,62 (m, 4H), 3,16 (q, 2H), 3,58 (s, 2H), 5,05 (s enlarged, 1H exchangeable with D_2O), 5,18 (s, 2H), 7,22-7,40 (m, 10H).

Example 14


This example describes the synthesis of N^1 -ethyl - N^1 -benzyl-hexan-1,6-diamine (XXII):



The compound XXII was obtained as a transparent oil from the acid {6-[ethyl-benzyl-amino]-hexyl}-carbamic benzyl ester (0.9 g; 2.45 mmol) following the same procedure described in example 3. Quantity yield; ^1H NMR (free base; CDCl_3) δ : 1,03 (t, 3H), 1,15 (s enlarged, 2H exchangeable with D_2O), 1,21-1,58 (m, 8H), 2,37-2,58 (m, 4H), 2,65 (t, 2H), 3,56 (s, 2H), 7,20-7,38 (m, 5H).

Example 15

This example describes the synthesis of the acid [6-(2-chloro-benzylamino-hexyl)-carbamic benzyl ester (XXIII):




The compound XXIII was obtained as a transparent oil from the acid (6-amino-hexyl)-carbamic benzyl ester (4.00 g, 16 mmol) following the same

procedure described in example 1. Yield 65%; ^1H NMR (free base; CDCl_3) δ : 1,23-1,60 (m, 8H), 2,41 (br, s 1H exchangeable with D_2O), 2,61 (t, 2H), 3,17 (q, 2H), 3,89 (s, 2H), 4,84 (s enlarged, 1H exchangeable with D_2O), 5,12 (s, 2H), 7,18-7,40 (m, 9H).

5 Example 16


This example describes the synthesis of the acid {6-[ethyl-(2-chloro-benzyl)-amino]-hexyl}-carbamic benzyl ester (XXIV):



The compound XXIV was obtained as a transparent oil from the acid [6-(2-chloro-benzylamino)-hexyl]-carbamic benzyl ester (2.00 g, 5.35 mmol) following 10 the same procedure described in example 2. Yield 40%; ^1H NMR (free base; CDCl_3) δ : 1,08 (t, 3H), 1,21-1,58 (m, 8H), 2,40-2,62 (m, 4H), 3,15 (q, 2H), 3,63 (s, 2H), 4,82 (s enlarged, 1H exchangeable with D_2O), 5,12 (s, 2H), 7,10-7,41 (m, 8H), 7,57 (d, 1H).

Example 17

15 This example describes the synthesis of N^1 -ethyl - N^1 -(2-chloro-benzyl)-hexan-1,6-diamine (XXV):




The compound XXV was obtained as a yellow oil from the acid {6-[ethyl-(2-chloro-benzyl)-amino]-hexyl}-carbamic benzyl ester (0.80 g; 1.99 mmol) following the same procedure described in example 3. Yield 98%; ^1H NMR (free 20 base; CDCl_3) δ : 1,05 (t, 3H), 1,12-1,54 (m, 8H + 2H exchangeable with D_2O), 2,38-2,66 (m, 6H), 3,61 (s, 2H), 7,05-7,37 (m, 3H), 7,53 (d, 1H).

Example 18

This example describes the synthesis of the acid [6-(2-nitro-benzylamino)-hexyl]-


carbamic benzyl ester (XXVI):



The compound XXVI was obtained as a transparent oil from the acid (6-amino-hexyl)-carbamic benzyl ester (5.00 g, 20 mmol) following the same procedure described in example 1. Yield 95%; ^1H NMR (free base; CDCl_3) δ : 1,27-5 1,38 (m, 4H), 1,42-1,60 (m, 4H + 1H exchangeable with D_2O), 2,62 (t, 2H), 3,18 (q, 2H), 4,02 (s, 2H), 4,89 (s enlarged, 1H exchangeable with D_2O), 5,12 (s, 2H), 7,24-7,42 (m, 6H), 7,58-7,66 (m, 2H), 7,95 (d, 1H).

Example 19


This example describes the synthesis of the acid {6-[ethyl-(2-nitro-benzyl)-amino]-hexyl}-carbamic benzyl ester (XXVII):



The compound XXVII was obtained as a greenish oil from the acid [6-(2-nitro-benzylamino)-hexyl]-carbamic benzyl ester (3.00 g, 7.79 mmol) following the same procedure described in example 2. Yield 40%; ^1H NMR (free base; CDCl_3) δ : 1,02 (t, 3H), 1,20-1,57 (m, 8H), 2,37-2,56 (m, 4H), 3,18 (q, 2H), 3,83 (s, 2H), 4,76 (s enlarged, 1H exchangeable with D_2O), 5,12 (s, 2H), 7,29-7,41 (m, 6H), 7,50-7,61 (m, 1H), 7,66-7,72 (m, 1H), 7,79-7,83 (m, 1H).

Example 20

This example describes the synthesis of N^1 -ethyl - N^1 -(2-nitro-benzyl)-hexan-1,6-diamine (XXVIII):




20 The compound XXVIII was obtained as a yellow oil from the acid {6-[ethyl-(2-nitro-benzyl)-amino]-hexyl}-carbamic benzyl ester (0.80 g; 2.00 mmol)

following the same procedure described in example 3. Yield 98%; ^1H NMR (free base; CDCl_3) δ : 1.02 (t, 3H), 1.20-1.57 (m, 8H), 2.05 (s enlarged, 2H exchangeable with D_2O), 2.37-2.56 (m, 4H), 2.73 (t, 2H), 3.83 (s, 2H), 7.32-7.41 (m, 1H), 7.50-7.61 (m, 1H), 7.70-7.76 (m, 1H), 7.79-7.83 (m, 1H).

5 Example 21


This example describes the synthesis of 2,5-bis-{6-[ethyl-(2-nitro-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XXIX):



The compound XXIX was obtained as a waxy red solid from $\text{N}^1\text{-ethyl-N}^1\text{-(2-nitro-benzyl)-hexan-1,6-diamine}$ (0.65 g; 2.33 mmol) and p-benzoquinone (0.12 g; 1.1 mmol) following the same procedure described in example 4. Yield 15%; ^1H NMR (free base; CDCl_3) δ : 0.98 (t, 6H), 1.19-1.50 (m, 12H), 1.52-1.72 (m, 4H), 2.35-2.57 (m, 8H), 3.13 (q, 4H), 3.83 (s, 4H), 5.30 (s, 2H), 6.58-6.66 (t enlarged, 2H exchangeable with D_2O), 7.32-7.41 (m, 2H), 7.48-7.58 (m, 2H), 7.62-7.70 (m, 2H), 7.78-7.82 (m, 2H). MS (ESI $^+$) m/z = 663 ($\text{M} + \text{H}$) $^+$.

15 Example 22

This example describes the synthesis of the acid [6-(3-methoxy-benzylamino-hexyl]-carbamic benzyl ester (XXX):




The compound XXX was obtained as a transparent oil from the acid (6-amino-hexyl)-carbamic benzyl ester (4.00 g, 16 mmol) following the same procedure described in example 1. Yield 76%; ^1H NMR (free base; CDCl_3) δ : 1.22-1.38 (m, 4H), 1.41-1.62 (m, 4H), 2.58 (s enlarged, 1H exchangeable with D_2O), 2.62 (t, 2H), 3.18 (q, 2H), 3.78 (s, 2H), 3.81 (s, 3H), 4.83 (s enlarged, 1H

exchangeable with D₂O), 5.08 (s, 2H), 6.79-6.95 (m, 3H), 7.20-7.41 (m, 6H).

Example 23


This example describes the synthesis of the acid {6-[ethyl-(3-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (XXXI):



The compound XXXI was obtained as a transparent oil from the acid [6-(3-methoxy-benzylamino)-hexyl]-carbamic benzyl ester (2.91 g, 7.85 mmol) following the same procedure described in example 2. Yield 50%; ¹H NMR (free base; CDCl₃) δ: 1.05 (t, 3H), 1.21-1.38 (m, 4H), 1.40-1.57 (m, 4H), 2.43 (t, 2H), 2.73 (t, 2H), 3.18 (q, 2H), 3.56 (s, 2H), 3.80 (s, 3H), 4.83 (s enlarged, 1H exchangeable with D₂O), 5.09 (s, 2H), 6.79-6.82 (m, 1H), 6.85-6.88 (m, 2H), 7.22 (t, 1H), 7.29-7.42 (m, 5H).

Example 24


This example describes the synthesis of N¹-ethyl-N¹-(3-methoxy-benzyl)-hexan-1,6-diamine (XXXII):



The compound XXXII was obtained as a transparent oil from the acid {6-[ethyl-(3-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (2.31 g; 6.01 mmol) following the same procedure described in example 3. Yield 90%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 3H), 1.22-1.65 (m, 8H + 2H exchangeable with D₂O), 2.38-2.58 (m, 4H), 2.65 (t, 2H), 3.58 (s, 2H), 3.82 (s, 3H), 6.72-6.92 (m, 3H), 7.16-7.29 (m, 1H).

Example 25


This example describes the synthesis of 2,5-bis-{6-[ethyl-(3-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XXXIII):



The compound XXXIII was obtained as a waxy red solid from N¹-ethyl-N¹-(3-methoxy-benzyl)-hexan-1,6-diamine (1.0 g; 4.24 mmol) and p-benzoquinone (0.2 g; 1.84 mmol) following the same procedure described in example 4. Yield 15%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 6H), 1.24-1.57 (m, 12H), 1.60-1.75 (m, 4H), 2.39-2.60 (m, 8H), 3.09 (q, 4H), 3.57 (s, 4H), 3.81 (s, 6H), 5.32 (s, 2H), 6.63 (t enlarged, 2H exchangeable with D₂O), 6.76-6.95 (m, 6H), 7.18-7.28 (t, 2H). MS (ESI⁺) m/z = 633 (M + H)⁺.

Example 26


This example describes the synthesis of the acid [6-(4-methoxy-benzylamino)-hexyl]-carbamic benzyl ester (XXXIV):



The compound XXXIV was obtained as a yellow oil from the acid (6-amino-hexyl)-carbamic benzyl ester (2.50 g, 10 mmol) following the same procedure described in example 1; yield 90%; ¹H NMR (free base; CDCl₃) δ: 1.25-1.38 (m, 4H), 1.41-1.57 (m, 4H + 1H exchangeable with D₂O), 2.62 (t, 2H), 3.19 (q, 2H), 3.75 (s, 2H), 3.82 (s, 3H), 4.76 (s enlarged, 1H exchangeable with D₂O), 5.12 (s, 2H), 6.82-6.93 (m, 2H), 7.20-7.43 (m, 7H).

Example 27

This example describes the synthesis of the acid {6-[ethyl-(4-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (XXXV):




The compound XXXV was obtained as a transparent oil from the acid [6-(2-methoxy-benzylamino)-hexyl]-carbamic benzyl ester (2.91 g, 7.85 mmol)

following the same procedure described in example 2. Yield 40%; ^1H NMR (free base; CDCl_3) δ : 1.07 (t, 3H), 1.23-1.38 (m, 4H), 1.42-1.57 (m, 4H), 2.42 (t, 2H), 2.56 (q, 2H), 3.21 (q, 2H), 3.52 (s, 2H), 3.82 (s, 3H), 4.83 (s enlarged, 1H exchangeable with D_2O), 5.12 (s, 2H), 6.84 (d, 2H), 7.25 (d, 2H), 7.32-7.42 (m, 5H).

Example 28


This example describes the synthesis of $\text{N}^1\text{-ethyl-N}^1\text{-(4-methoxy-benzyl)-hexan-1,6-diamine (XXXVI):}$



The compound XXXVI was obtained as a transparent oil from the acid {6-[ethyl-(4-methoxy-benzyl)-amino]-hexyl}-carbamic benzyl ester (2.31 g; 6.01 mmol) following the same procedure described in example 3. Quantity yield; ^1H NMR (free base; CDCl_3) δ : 1.06 (t, 3H), 1.22-1.56 (m, 8H + 2H exchangeable with D_2O), 2.38-2.57 (m, 4H), 2.66 (t, 2H), 3.55 (s, 2H), 3.81 (s, 3H), 6.82-6.94 (m, 2H), 7.20-7.31 (m, 2H).

Example 29

This example describes the synthesis of 2,5-bis-{6-[ethyl-(4-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XXXVII):




The compound XXXVII was obtained as a waxy red solid from $\text{N}^1\text{-ethyl-N}^1\text{-(4-methoxy-benzyl)-hexan-1,6-diamine (1.05 g; 4 mmol)}$ and p-benzoquinone (0.2 g; 1.84 mmol) following the same procedure described in example 4. Yield 12%; ^1H NMR (free base; CDCl_3) δ : 1.04 (t, 6H), 1.22-1.56 (m, 12H), 1.58-1.72 (m, 4H), 2.38-2.56 (m, 8H), 3.12 (q, 4H), 3.47 (s, 4H), 3.79 (s, 6H), 5.32 (s, 2H),

6.59 (t enlarged, 2H exchangeable with D₂O), 6.82-6.93 (m, 4H), 7.21-7.30 (m, 4H). MS (ESI⁺) *m/z* = 633 (M + H)⁺.

Example 30

This example describes the synthesis of the acid {6-[(furan-2-ilmethyl)amino]-


5 hexyl}-carbamic benzyl ester (XXXVIII):



The compound XXXVIII was obtained as a brown solid from (6-amino-hexyl)-carbamic benzyl ester (4.00 g, 16 mmol) following the same procedure described in example 1. Yield 72%; ¹H NMR (free base; CDCl₃) δ: 1.22-1.50 (m, 8H), 1.73-1.98 (m, 2H + 1H exchangeable with D₂O), 2.69-2.94 (m, 2H), 3.18 (q, 2H), 4.28 (s, 2H), 4.99-5.18 (m, 2H + 1H exchangeable with D₂O), 6.39-6.42 (m, 1H), 6.72-6.79 (m, 1H), 7.28-7.40 (m, 5H), 7.46-7.50 (m, 1H). P.f. = 132-135 °C.

Example 31


This example describes the synthesis of the acid [6-(ethyl-furan-2-ilmethyl-amino)-hexyl]-carbamic benzyl ester (XXXIX):



15 The compound XXXIX was obtained as a yellow oil from the acid {6-[(furan-2-ilmethyl)amino]-hexyl}-carbamic benzyl ester (2.70 g, 8.18 mmol) following the same procedure described in example 2. Yield 35%; ¹H NMR (free base; CDCl₃) δ: 1.15-1.60 (m, 9H), 1.82-1.99 (m, 2H), 2.79-2.88 (m, 2H), 2.99 (q, 2H), 3.21 (q, 2H), 4.22 (s, 2H), 4.96 (s enlarged, 1H exchangeable with D₂O), 5.15 (s, 2H), 6.43-6.49 (m, 1H), 6.62-6.68 (m, 1H), 7.32-7.41 (m, 5H), 7.53-7.56 (m, 1H).

Example 32


This example describes the synthesis of N¹-ethyl-N¹-furan-2-ilmethyl-hexan-1,6-diamine (XL):



The compound XL was obtained as a transparent oil from the acid [6-(ethyl-furan-2-ilmethyl-amino)-hexyl]-carbamic benzyl ester (1.05 g; 2.92 mmol) following the same procedure described in example 3. Yield 85%; ¹H NMR (free base; CDCl₃) δ: 1.08 (t, 3H), 1.22-1.58 (m, 8H + 2H exchangeable with D₂O), 2.38-2.61 (m, 4H), 2.67 (t, 2H), 3.62 (s, 2H), 6.18-6.20 (m, 1H), 6.32-6.38 (m, 1H), 7.38-7.42 (m, 1H).

Example 33


This example describes the synthesis of 2,5-bis-[6-(ethyl-furan-2-ilmethyl-amino)-hexylamino]-[1,4]benzoquinone (XLI):



The compound XLI was obtained as a waxy red solid from N¹-ethyl-N¹-furan-2-ilmethyl-hexan-1,6-diamine (0.55 g; 2.45 mmol) and p-benzoquinone (0.14 g; 1.23 mmol) following the same procedure described in example 4. Yield 16%; ¹H NMR (free base; CDCl₃) δ: 1.09 (t, 6H), 1.22-1.58 (m, 12H), 1.60-1.73 (m, 4H), 2.43 (t, 4H), 2.57 (q, 4H), 3.18 (q, 4H), 3.63 (s, 4H), 5.32 (s, 2H), 6.18-6.22 (m, 2H), 6.32-6.39 (m, 2H), 6.62 (t enlarged, 2H exchangeable with D₂O), 7.38-7.41 (m, 2H). MS (ESI⁺) *m/z* = 553 (M + H)⁺.

Example 34

This example describes the synthesis of the acid [2-(2-methoxy-benzylamino-ethyl]-carbamic benzyl ester (XLII):




The compound XLII was obtained as a yellow oil from the acid (2-aminoethyl)-carbamic benzyl ester (5.00 g, 25.8 mmol) following the same procedure described in example 1. Yield 80%; ¹H NMR (free base; CDCl₃) δ: 1.63 (s

enlarged, 1H exchangeable with D₂O), 2.75 (t, 2H), 3.33 (q, 2H), 3.78 (s, 2H), 3.83 (s, 3H), 5.18 (s, 2H), 5.38 (s enlarged, 1H exchangeable with D₂O), 6.82-6.93 (m, 2H), 7.20-7.41 (m, 7H).

Example 35


5 This example describes the synthesis of the acid {2-[ethyl-(2-methoxy-benzyl)-amino]-ethyl}-carbamic benzyl ester (XLIII):



The compound XLIII was obtained as a transparent oil from the acid [2-(2-methoxy-benzylamino)-ethyl]-carbamic benzyl ester (2.00 g, 19.7 mmol) following the same procedure described in example 2. Yield 45%; ¹H NMR (free base; CDCl₃) δ: 1.05 (t, 3H), 2.58 (q, 2H), 2.62 (t, 2H), 3.38 (q, 2H), 3.62 (s, 2H), 3.82 (s, 3H), 5.20 (s, 2H), 5.78 (s enlarged, 1H exchangeable with D₂O), 6.85-6.99 (m, 2H), 7.23-7.44 (m, 7H).

Example 36


This example describes the synthesis of N¹-ethyl-N¹-(2-methoxy-benzyl)-ethan-1,2-diamine (XLIV):



The compound XLIV was obtained as a transparent oil from the acid {2-[ethyl-(2-methoxy-benzyl)-amino]-ethyl}-carbamic benzyl ester (1.50 g; 4.35 mmol) following the same procedure described in example 3. Yield 98%; ¹H NMR (free base; CDCl₃) δ: 1.04 (t, 3H), 2.00 (s enlarged, 2H exchangeable with D₂O), 2.65 (q, 2H), 2.98 (t, 2H), 3.21 (t, 2H), 3.78 (s, 2H), 3.85 (s, 3H), 6.85-7.01 (m, 2H), 7.20-7.42 (m, 2H).

Example 37


This example describes the synthesis of 2,5-bis-{2-[ethyl-(2-methoxy-benzyl)-amino]-ethylamino}-[1,4]benzoquinone (XLV):



The compound XLV was obtained as a dark red solid from N¹-ethyl-N¹-(2-methoxy-benzyl)-ethan-1,2-diamine (1,40 g; 6.27 mmol) and p-benzoquinone (0.34 g; 3.12 mmol) following the same procedure described in example 4. Yield 10%;
 5 ¹H NMR (free base; CD₃OD) δ: 1.15 (t, 6H), 2.64 (q, 4H), 2.79 (t, 4H), 3.71 (s, 4H), 3.82 (s, 6H), 5.28 (s, 2H), 6.88-6.99 (m, 4H), 7.21-7.38 (m, 4H). MS (ESI⁺) m/z = 521 (M + H)⁺. Pf: 127-130 °C.

Example 38


10 This example describes the synthesis of the acid [7-(2-methoxy-benzylamino-heptyl]-carbamic benzyl ester (XLVI):



15 The compound XLVI was obtained as a yellow oil from the acid (7-amino-heptyl)-carbamic benzyl ester (2,50 g, 9.4 mmol) following the same procedure described in example 1. Yield 90%; ¹H NMR (free base; CDCl₃) δ: 1.22-1.38 (m, 6H), 1.38-1.64 (m, 4H + 1H exchangeable with D₂O), 2.62 (t, 2H), 3.13 (q, 2H), 3.81 (s, 3H), 3.84 (s, 2H), 5.09 (s, 2H), 5.22 (s enlarged, 1H exchangeable with D₂O), 6.80-6.93 (m, 2H), 7.19-7.40 (m, 7H).

Example 39

This example describes the synthesis of the acid {7-[ethyl-(2-methoxy-benzyl)-amino]-heptyl}-carbamic benzyl ester (XLVII):




The compound XLVII was obtained as a transparent oil from the acid [7-(2-methoxy-benzylamino)-heptyl]-carbamic benzyl ester (3.30 g, 8.0 mmol) following the same procedure described in example 2. Yield 35%; ^1H NMR (free base; CDCl_3) δ : 1.12 (t, 3H), 1.25-1.38 (m, 6H), 1.43-1.61 (m, 4H), 2.45-2.61 (m, 4H), 3.20 (q, 2H), 3.65 (s, 2H), 3.83 (s, 3H), 5.02 (s enlarged, 1H exchangeable with D_2O), 5.19 (s, 2H), 6.84-7.02 (m, 2H), 7.21-7.51 (m, 7H).

Example 40

This example describes the synthesis of $\text{N}^1\text{-ethyl-N}^1\text{-(2-methoxy-benzyl)-heptan-1,7-diamine}$ (XLVIII):

10




15

The compound XLVIII was obtained as a yellow oil from the acid {7-[ethyl-(2-methoxy-benzyl)-amino]-heptyl}-carbamic benzyl ester (1.10 g; 2.50 mmol) following the same procedure described in example 3. Quantity yield; ^1H NMR (free base; CDCl_3) δ : 0.98 (t, 3H), 1.12-1.53 (m, 10H + 2H exchangeable with D_2O), 2.35-2.52 (m, 4H), 2.55-2.63 (m, 2H), 3.55 (s, 2H), 3.72 (s, 3H), 6.72-6.80 (m, 1H), 6.83 (t, 1H), 7.14 (t, 1H), 7.38 (d, 1H).

Example 41

This example describes the synthesis of 2,5-bis-{7-[ethyl-(2-methoxy-benzyl)-amino]-heptyl-amino}-[1,4]benzoquinone (IL):

20



25


The compound IL was obtained as a red oil from $\text{N}^1\text{-ethyl-N}^1\text{-(2-methoxy-benzyl)-heptan-1,7-diamine}$ (0.90 g; 3.23 mmol) and p-benzoquinone (0.17 g; 1.57 mmol) following the same procedure described in example 4. Yield 12%; ^1H NMR (free base; CDCl_3) δ : 1.08 (t, 6H), 1.28-1.42 (m, 12H), 1.45-1.60 (m, 4H), 1.62-

- 35 -

1.75 (m, 4H), 2.48 (t, 4H), 2.58 (q, 4H), 3.18 (q, 4H), 3.62 (s, 4H), 3.83 (s, 6H),
 5.35 (s, 2H), 6.62 (t enlarged, 2H exchangeable with D₂O), 6.85-6.90 (m, 2H), 6.97
 (t, 2H), 7.22 (t, 2H), 7.43 (d, 2H). MS (ESI⁺) *m/z* = 661 (M + H)⁺.

Example 42

5 This example describes the synthesis of N-(2-methoxy-benzyl)-hexan-1,6-diamine (L):




The compound L was obtained as a yellow oil from the acid [6-(2-methoxy-benzylamino-hexyl]-carbamic benzyl ester (2.0 g; 5.40 mmol) following the same procedure described in example 3. Yield 65%; ¹H NMR (free base; CDCl₃) δ: 1.12-1.42 (m, 8H + 3H exchangeable with D₂O), 2.38-2.56 (m, 4H), 3.60 (s, 2H), 3.62 (s, 3H), 6.63-6.79 (m, 2H), 7.01-7.15 (m, 2H).

Example 43

This example describes the synthesis of 2,5-bis-[6-(2-methoxy-benzylamino)-hexylamino]-[1,4]-benzoquinone (LI):


15



The compound LI was obtained as a red solid from N-(2-methoxy-benzyl)-hexan-1,6-diamine (0.70 g; 2.96 mmol) and p-benzoquinone (0.15 g; 1.38 mmol) following the same procedure described in example 4. Yield 18%; ¹H NMR (free base; CDCl₃) δ: 1.28-1.42 (m, 8H), 1.52-1.76 (m, 8H), 2.63 (t, 4H), 3.16 (q, 4H), 3.78-3.85 (m, 10 + 2H exchangeable with D₂O), 5.32 (s, 2H), 6.62 (t enlarged, 2H exchangeable with D₂O), 6.85-6.96 (m, 4H), 7.22-7.35 (m, 4H). MS (ESI⁺) *m/z* = 577 (M + H)⁺. Pf: 205 °C.

Example 44


This example describes the synthesis of the acid {6-[(2-methoxy-benzyl)-methyl-amino]-hexyl}-carbamic benzyl ester (LII):



To a suspension of the acid [6-(2-methoxy-benzylamino-hexyl]-carbamic benzyl ester (5.0 g; 13.5 mmol) in 8 ml of H₂O are added HCOOH (1.6 ml; 40.5 mmol) and HCHO (3.1 ml; 40.5 mmol). It was left in agitation by reflux for 6 hours and at e.t. for one night, then the aqueous solution was basified with NaOH 40% and extracted with CHCl₃ (3 x 100 ml). The collected and anhydriified organic extracts were evaporated in a vacuum and the residue obtained was purified by flash chromatography. Eluting with CHCl₃/ether of petroleum/MeOH/NH₄OH (8:2:0.7:0.05) obtained 1.6 g of the compound LII as a yellow oil. Yield 75%; ¹H NMR (free base, CDCl₃) δ: 1,23-1,39 (m, 4H), 1,40-1,63 (m, 4H), 2,23 (s, 3H), 2,44 (t, 2H), 3,17 (q, 2H), 3,58 (s, 2H), 3,82 (s, 3H), 5,12 (s, 2H), 5,22 (s enlarged, 1H exchangeable with D₂O), 6,82-7,00 (m, 2); 7,20-7,38 (m, 7).

Example 45

This example describes the synthesis of N¹-(2-methoxy-benzyl)-N¹-methyl-1,6 hexandiamine (LIII):




The compound LIII was obtained as a yellow oil from the acid {6-[(2-methoxy-benzyl)-methyl-amino]-hexyl}-carbamic benzyl ester (1.60 g; 4.20 mmol) following the same procedure described in example 3. Quantity yield; ¹H NMR (free base; CDCl₃) δ: 1.18-1.56 (m, 8H + 2H exchangeable with D₂O), 2.18 (s, 3H), 2.38 (t, 2H), 2.62 (t, 2H), 3.45 (s, 2H), 3.78 (s, 3H), 6.78-6.92 (m, 2H), 7.19 (t, 1H),

7.28-7.31 (m, 1H).

Example 46


This example describes the synthesis of 2,5-bis-{6-[(2-methoxy-benzyl)-methylamino]-hexylamino}-[1,4]-benzoquinone (LIV).



The compound LIV was obtained as a waxy red solid from N¹-(2-methoxy-benzyl)-N¹-methyl-1,6 hexandiamine (0.90 g; 3.60 mmol) and p-benzoquinone (0.18 g; 1.66 mmol) following the same procedure described in example 4. Yield 10%; ¹H NMR (free base; CDCl₃) δ: 1.31-1.48 (m, 16H), 2.22 (s, 6H), 2.41 (t, 4H), 3.15 (q, 4H), 3.52 (s, 4H), 3.83 (s, 6H), 5.32 (s, 2H), 6.62 (t enlarged, 2H exchangeable with D₂O), 6.83-6.99 (m, 4H), 7.19-7.38 (m, 4H). MS (ESI⁺) m/z = 605 (M + H)⁺.

Example 47

This example describes the synthesis of 2,5-bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexylamino}-3,6-dimethyl-[1,4]-benzoquinone (LV).



The compound LV was obtained as a red oil from N¹-(2-methoxy-benzyl)-N¹-ethyl-1,6 hexandiamine (0.82 g; 3.10 mmol) and 2,5-dimethyl-benzoquinone (0.20 g; 1.85 mmol) following the same procedure described in example 4. Yield 10%; ¹H NMR (free base; CDCl₃) δ: 1.12 (t, 6H), 1.22-1.43 (m, 8H), 1.45-1.63 (m, 8), 2.11 (s, 6H), 2.48-2.62 (m, 8H), 3.53 (q, 4H), 3.63 (s, 4H), 3.83 (s, 6H), 6.72 (t enlarged, 2H exchangeable with D₂O), 6.83-7.01 (m, 4H), 7.23 (t, 2H), 7.42 (m, 2H). MS (ESI⁺) m/z = 661 (M + H)⁺.

Example 48

This example describes the determination of the inhibiting capacity and of the selectivity of the compounds XVI and XII and the comparison of these properties with some drugs present on the market.

5 The inhibiting power (IC_{50}) was determined using Ellman's spectrophotometric method (Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. *Biochem. Pharmacol.* 1961, Vol. 7, p. 88-95).

The value of IC_{50} was determined using constant concentrations of substratum and enzyme and varying the concentration of an inhibitor with successive increases. In this way the activity of the enzyme was determined on the basis of revelations of the formation of an anionic coloured molecular species (2-nitro 4-thiobenzoate) ($\lambda_{max} = 412$ nm), which is obtained following the reaction between thiacholine – a product of the enzymatic hydrolysis of acetylthiocholine 10 (substratum of AChE) or butyrylthiocholine (substratum of BuChE) - and 5,5' dithio-bis-nitrobenzoic acid (Ellman's reactive). The variation of absorbance at 412 nm (that is the variation of the absorbance of 2-nitro 4-thiobenzoate per minute 15 ($\Delta A/min$) (enzymatic speed) depends on the substratum concentration, and on the enzymatic activity of AChE (from human erythrocytes, amphiphilic form, EC 3.1.1.7) and BuChE (from human serum, EC 3.1.1.8), according to the kinetic of Michaelis Menten.

To calculate the IC_{50} , constant concentrations of saturating substratum were used, that is which were able to produce maximum enzymatic speed (V_{max}) and fixed enzyme rates. Five growing concentrations of the compounds under study were 20 then tested, able to induce inhibitions of between 20% and 1'80% of the V_{max} . Lines of inhibition were next obtained, plotting on a graph the percentage of inhibition of the V_{max} as a function of the decimal logarithm of the nanomolar concentration of

the inhibitor. The parameters of linear regression were assessed for each line and the IC₅₀ (the concentration able to inactivate the maximum enzymatic activity by 50%), which was obtained by interpolation on the respective line.

Table I

Inhibitor	IC ₅₀ (AChE) (nM)	IC ₅₀ (BuChE) (nM)	Selectivity IC ₅₀ (BuChE) / IC ₅₀ (AChE)
XII	3.19 ± 0.15 ^a	4490 ± 340 ^a	1407
XVI	2.39 ± 0.14 ^a	1440 ± 100 ^a	602
Tacrine	250 ± 10	50 ± 2	0.2
Donepezil	5.7 ^b	~7000 ^b	~1200

5 ^a Mean of two independent measurements, repeated in triplicate;

^b Sugimoto, H.; Yamanishi, Y.; Iimura, Y.; Kawakami, Y.; Donepezil hydrochloride (E2020) and other Acetylcholinesterase inhibitors. Current Medicinal Chemistry 2000, vol. 7, p.303-339.

Table I shows the IC₅₀ obtained using the method described above and relating to the compounds XVI, XII, to Tacrine and to Donepezil. The IC₅₀ for the AChE are indicated as IC_{50(AChE)}, the IC₅₀ for BuChE are indicated as IC_{50(BuChE)}. The selectivity is defined as the ratio between IC_{50(AChE)} and IC_{50(BuChE)} and indicates the inhibitor's ability to bind preferably with AChE rather than with BuChE.

Compounds XVI and XII showed a relatively very good IC_{50(AChE)} (Table I), two times smaller than the IC_{50(AChE)} of Tacrine (Cognex[®]) and substantially lower than that of Donepezil (Aricept[®]).

The selectivity was relatively very good, higher than that of Tacrine and comparable to that of Donepezil.

Example 49

20 This example describes the determination of an inhibiting constant (K_i) of the compound XVI.

The assessment of the kinetic of an inhibitor can supply important

information on the nature of the bond between enzyme and inhibitor, the site or sites of the bond and the quantitative efficacy of the bond, expressed by K_i . K_i in fact describes the state of equilibrium between a free enzyme (in the particular case AChE, from human erythrocytes EC 3.1.1.7), an inhibitor (in the particular case the compound XVI) and the enzyme-inhibitor complex, representing the disassociation constant of the enzyme-inhibitor complex.

The determination of the K_i of the complex AChE-compound XVI was realised using the method of Lineweaver-Burk (Dixon, M., Webb, E.C., *Enzymes*, Second Edition, Chapter VIII, p. 315, Longmans, Green and Co. Ltd, 1964, London, UK). For each concentration of the compound XVI the enzymatic activity was assessed with the variation of the concentration of the substratum acetylthiocholine (111-550 μ M). The data obtained on enzymatic activity were plotted on a graph (figure 1) showing for each concentration of the compound XVI, the reciprocal of the speed as a function of the inverse of the concentration of the substratum. The values of the gradients of the lines obtained for each concentration of inhibitor were then plotted on a graph (figure 2) as a function of the corresponding concentration of inhibitor. The intercept on the axis of the X-coordinates of the line obtained, not passing through zero, gave a value of K_i equal to 2.6 nM for the compound XVI.

From the analysis of the graph of Lineweaver-Burk (figure 1) lines with growing gradients can be seen which show a change of both V_{max} and K_i in the presence of an inhibitor. This behaviour probably indicates a competitive inhibition of a mixed type, which springs from a significant interaction of the compound XVI both with the free enzyme and with the acetylated enzyme. From these results it seems that the compound XVI has a relatively strong interaction, not only with the active site, but also with another accessory site, potentially represented by the peripheral site of the enzyme. The compound XVI is therefore a relatively

- 41 -

powerful, reversible, rapid, competitive inhibitor of a mixed type, which substantially follows the kinetic of Michaelis-Menten.

Example 50

The compounds in the following table were tested with the method of Ellman (see 5 example 48) with recombining human AChE (HuAChE, EC 3.1.1.7) and on BuChE (from human serum, EC 3.1.1.8).

The table also shows the data concerning the inhibiting power of two reference compounds, Tacrine and Donepezil, tested in the same experimental conditions, and of the compounds XVI and XII.

Compound	IC ₅₀ (HuAChE) nM*	IC ₅₀ (BuChE) nM*
XLV	61.5±1.3	16800±1100
XII	2.25±0.21	4490±340
XVI	1.55±0.11	1440±100
IL	7.79±0.37	1250±250
LIV	77.8±4.3	5110±410
LI	123±20	3230±150
LV	9.50±0.23	462±2
XVII	73.3±3.2	645±33
XXXVII	51.1±1.0	2420±940
XXXIII	13.8±1.7	2170±70
XXIX	2310±130	36500±8800
XVIII	593±51	45100±1000
XLI	144±3	3510±180
Tacrine	424±21	50±2
Donepezil	23.1±4.8	7420±390

10 * Mean of two independent measurements, repeated in triplicate.

Example 51

This example describes the determination of the amyloid anti-aggregating power of the compound XVI.

Since the induction of the formation of fibrils of A β by the AChE seems to occur by interaction between a peripheral site of the enzyme and the peptide (Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M. et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. *Neuron* 1996, Vol. 16, p. 881-891), and since the compound XVI seems to bind with this site, the ability of the compound XVI to inhibit the interaction between enzyme and A β and therefore to block the formation of fibrils induced by AChE was assessed. To do this a fluorimetric method was used which is able to highlight the ability of the AChE (recombinant human, EC 3.1.1.7) to promote the formation of fibrils of the peptide A β (1-40).

Firstly A β (230 μ M) was incubated with the enzyme (2.3 μ M) in a molar ratio of 100:1, at environment temperature an aqueous phosphate buffer with pH = 8.0, 0.215 M. To assess the formation of fibrils induced by AChE, the incubated solution was transferred into 2 ml of buffer with pH = 8.5 composed of glycine-sodium hydroxide (50 mM), containing thioflavine T (1.5 μ M). Thioflavine T interacts selectively with the fibrils of A β in beta conformation, developing a characteristic fluorescence. The intensity of fluorescence of this solution (λ_{em} = 490 nm), after 300 s, was acquired, fixing the λ_{exc} = 446 nm. A fluorescence scan of 300 s was then carried out to obtain a stable value of the fluorescent signal, from which was subtracted the contribution to the basic fluorescence of thioflavine T. To obtain the value of the intensity of fluorescence, relating only to the interaction of thioflavine T with the amyloid fibrils, the contributions of whites composed of A β and AChE incubated individually in the same conditions were subtracted.

Then, after having checked the conditions of aggregation of β A induced by AChE, the anti-aggregating power of the compound XVI was checked in the same conditions. The compound was incubated together with A β and AChE, in the same conditions described above. The concentration of the compound XVI was varied 5 between 10 μ M and 250 μ M. In the presence of the compound XVI there was a lowering of the specific signal of intensity of fluorescence of thioflavine complexed with the fibrils of A β , indicating an amyloid anti-aggregating effect. The signal of fluorescence was directly proportional to the logarithm in base ten of the concentration of the compound XVI. The concentration of the compound XVI able 10 to reduce the signal of fluorescence by 50% was equal to 28.3 \pm 0.3 μ M (figure 3).

Among other AChE inhibiting compounds (that is Tacrine, Donepezil, physostigmine, propidium, decamethonium) tested in the conditions described, only propidium showed an inhibiting power ($IC_{50} = 12.6\pm0.3 \mu$ M) of the same magnitude as the inhibiting power of the compound XVI. On this point it is 15 important to stress that propidium is described as a non competitive inhibitor of AChE, able to bind selectively with the peripheral site of the enzyme (Taylor, P.; Lappi, S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 1975, Vol. 14, p. 1989-1997). The anti-aggregating behaviour of the compound XVI therefore confirms that this 20 molecule is able to establish binding interactions with the peripheral site of AChE, which has a high affinity for A β .

Example 52

Following a method similar to the one described in the previous example, it was experimentally determined that the compound XII with a concentration of 100 25 μ M exerts an inhibition of about 90% on the aggregation induced by AChE %.

Example 53

This example describes the comparison between the pIC_{50} of 2,5-bis-diamine-

[1,4]benzoquinonic derivatives represented by the general formula (I) and known compounds having a general formula (LVI):




Table 2

No.	R ₆	R ₇	R ₈	A	E	pIC ₅₀ (AChE)	pIC ₅₀ (BChE)
1	2-MeOC ₆ H ₅ CH ₂	H	H	H ₂	S-S	5.14±0.02	5.21±0.03
2	H		H	H ₂	S-S	3.30±0.03	3.19±0.02
3	2-MeOC ₆ H ₅ CH ₂	H	H	H ₂	CH ₂	5.14±0.03	5.06±0.02
4	2-MeOC ₆ H ₅ CH ₂	H	H	H ₂	(CH ₂) ₂	5.19±0.01	5.86±0.01
5	2-MeOC ₆ H ₅ CH ₂	H	H	H ₂	(CH ₂) ₃	5.35±0.05	5.43±0.02
6	2-MeOC ₆ H ₅ CH ₂	H	H	H ₂	(CH ₂) ₄	5.27±0.03	6.01±0.02
7	2-MeOC ₆ H ₅ CH ₂	H	H	O	(CH ₂) ₄	5.73±0.03	4.94±0.03
8	2-MeOC ₆ H ₅ CH ₂	H	Me	O	(CH ₂) ₄	6.51±0.02	5.22±0.04
9	2-MeOC ₆ H ₅ CH ₂	Me	Me	O	(CH ₂) ₄	6.77±0.01	4.93±0.04
XII						≈ 8.49	≈ 5.35
XVI						≈ 8.62	≈ 5.84

5 (The compounds having a general formula LVI are described in Melchiorre et al., Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease, J. Med. Chem. 1998, vol. 41, 4186-4189).

It may be seen from table 2 that the 2,5-bis-diamine-[1,4]benzoquinonic derivatives represented by the general formula (I) present lower IC₅₀(AChE) and higher selectivity than the known compounds having a general formula (LVI).

Example 54

This example describes an assessment of the activity of the compound XVI in an animal model.

The tests in vivo were carried out using a recently realised animal model (Ruberti F, et al., J Neurosci 2000, Vol. 20, p. 2589-2601), which presents a 5 phenotype strongly resembling Alzheimer's disease in man. In particular, the model consists of a transgenic mouse which expresses antibodies for the nerve growth factor (NGF), and consequently shows an extensive neuron loss in the cortex, formation of plaques of amyloid β and of intracellular neurofibrillar tangles, as well as dysfunctions in behaviour.

10 In particular, to produce the anti-NGF transgenic mice (AD11), the variable regions of the light and heavy chains of the anti-NGF monoclonal antibody α D11 were linked to the constant human regions k and γ 1, to give the chimerical man/rat antibody α D11, and were then placed under the transcriptional control of the promoter of the precocious region of the human cytomegalovirus (CMV). Mice 15 expressing functional anti-NGF antibodies (AD11 mice) were obtained by crossing mice that expressed the light chain (CMV-VK α D11) with mice that expressed the heavy chain (CMV-VH α D11).

20 The AD11 mice were treated with the compound XVI (7 mg/kg in saline solution) via intraperitoneal injection daily for 15 days from age 1.5 months to 2 months. Two control groups were considered: AD11 mice of the same litter treated with saline solution and non transgenic mice of the same stock and the same age.

25 The immunohistochemical tests were carried out as follows. The AD11 mice treated with the compound XVI, those treated with mice that expressed the and the non transgenic mice were anaesthetised with an overdose of chloral hydrate. The brain was removed and fixed for 24 h in a solution of 4% paraformaldehyde in phosphate buffer (PBS) and then cryoprotected in 30% sucrose. Coronal sections of the basal forebrain and of the entorhinal cortex were cut with a thickness of 40 μ m

and collected in 6-cell plates containing 1% paraformaldehyde in PBS. The following primary antibodies were used for the immunohistochemical analysis: anti-choline acetyltransferase (1:500, Chemicon Inc., Temecula, CA), anti-phosphorylated tau protein (clone AT8, Innogenetics N.V. Zwijnaarde, Belgium) 5 and anti-protein precursor of amyloid (clone 2.F2.19B4 Chemicon Inc.). After incubation with the primary antibodies, the sections were washed before adding a biotinilated antibody against goat IgG (1:200, Vector Laboratories, Burlingame, CA) or against mouse IgG (Dako A/S, Glostrup, Denmark).

A stereological analysis was carried out to determine the number of 10 cholinergic neurons positive to choline acetyltransferase (ChAT). The volume of the basal forebrain was calculated using the Cavalieri method described by Michel and Cruz-Olive (J Microsc 1988, Vol. 150, p. 117-146) and by Peterson et al. (J Comp Neurol 1999, Vol. 404, p. 1-20), while an estimate of the total number of 15 neurons positive to ChAT was obtained using the optical fractionation method (West MJ, Neurobiol Aging 1993, Vol. 14, p. 275-285 ; Peterson DA, et al., J Comp Neurol 1999, Vol. 404, p. 1-20).

To determine whether XVI can prevent the loss of ChAT positive neurons in 20 the basal forebrain and in the basal nucleus of Meynert, the compound was administered daily to AD11 mice at a very early stage of neurodegeneration (from 1.5 months to 2 months; n = 6). From the figures 4A-4C it can be seen that the treatment was able to prevent the cholinergic deficit in the basal forebrain; the same result was quantified from the stereological calculations summed up in the graph in figure 5. Moreover, XVI was efficacious in preventing the loss of cholinergic 25 neurons in the basal nucleus of Meynert, as indicated by the data shown in the graph in figure 6.

As regards other AD markers, the effect of XVI on the deposition of the amyloid β precursor protein (APP) and on tau protein hyperphosphorylation in

AD11 mice of 2 months was examined. At age 2 months, APP deposition in the cerebral vessels is absent in the control mice (Fig. 7A), but important in the AD11 mice (Fig. 7B). APP deposition in the cerebral vessels is relatively prevented following the administration of XVI (Fig. 7C). From the comparison of Figs. 7A, 5 7B and 7C, it may be deduced that the compound XVI was able to reduce markedly the cerebrovascular deposition of APP following administration for 15 days. To determine whether the compound XVI can prevent or recover tau hyperphosphorylation in the cortex, an immunohistochemical test was carried out on sections obtained from treated AD11 mice of 2 months and mice treated with 10 the vehicle alone. While the control mice do not show hyperphosphorylated tau in the somatodendritic cellular compartment (Fig. 8A), the AD11 animals not treated or treated with the vehicle show an intense marking in the neuronal body (Fig. 4B). Tau hyperphosphorylation is partly prevented following the administration of XVI (Fig. 4C).

15 On conclusion of the experimental tests carried out *in vivo* in a transgenic model of AD, it may be said that the compounds of the invention present an activity profile compatible with the recovery of cholinergic functionality (increase of ChAT positive neurons) and the decrease of AD markers (decrease of the cerebrovascular deposition of APP and of tau hyperphosphorylation).

20 **Example 55**

This example describes further assessments of the activity *in vivo* of the compound XVI in an animal model.

Doses and means of Administration

25 The compound XVI was dissolved in ethanol at a dose 50 times more concentrated than the one to be administered to the animal and then diluted in saline solution, for intraperitoneal injections, or in water, for oral administration.

To test its efficacy after oral administration, the compound XVI was

administered in AD11 mice aged 15 months at a dose of 7 mg/kg/day.

To analyse the efficacy of the compound XVI in treating cognitive deficit in AD11 mice at age 6 and 12 months and in preventing the amnesia induced by scopolamine (Weiss B, Heller A. Methodological problems in evaluating the role of cholinergic mechanisms in behavior. Fed Proc 28, 135-146, 1969) a dose of 15 mg/kg/day was used, administered for 15 days.

At age 2 and 6 months, the capacity of the compound XVI in improving the Alzheimer phenotype in AD11 mice was compared to that of other inhibitors of AChE and of NGF. The mice received a daily injection of the compound XVI in a dose of 7 mg/kg. Only in the case of behavioural analysis did they receive a dose of 15 mg/kg/day per os.

Tacrine was administered by intraperitoneal injection in a dose of (0.1 mg/kg/day and 3.5 mg/kg/day) from age 1.5 months for 15 days, while Galantamine was administered by intraperitoneal injection for the same period and from age 6 months. Moreover, it was administered for 4 months from age 2 months per os (3.5 mg/kg/day).

In all the experiments the control mice were age-matched non transgenic mice, age-matched AD11 mice to which saline solution was administered via intraperitoneal injection or water containing the same percentage of ethanol present in the solution of the compound XVI.

Histology and neurostereology

At the end of the treatment, the mice were anaesthetised with 8µl/gr of chloral hydrate. The brain was removed and placed in an ice-cold petri dish. The encephalon was fixed in 4% paraformaldehyde in phosphate buffer for 24 hours and then cryoprotected in a solution of 30% sucrose in phosphate buffer.

Coronal brain sections were obtained with a sliding freezing microtome. Serial sections were collected in a solution of 1% paraformaldehyde in phosphate

buffer.

To evaluate the effects on morphological alterations, sections were incubated with the following primary antibodies against choline acetyltransferase (Anti-ChAT; Chemicon), amyloid precursor protein APP (Chemicon), the phosphorylated fraction of tau protein (clone AT8; Innogenetics), the N terminus of β-amyloid (Santa Cruz).

Neurostereological quantitative analysis was performed on the basal forebrain and entorhinal cortex using the optical fractionation method (West M.J., Neurobiol Aging 14, 275-285, 1993; Peterson D.A. et al. J Comp Neurol 404, 1-20, 1999; Michel R.P. & Cruz-Orive L.M. J. Microsc. 150, 117-136, 1988) .

The density of extracellular deposits of APP was calculated according to the method used by Schenk (Schenk D., Nature 400, 173-177, 1999), in which the percentage of the cortical area occupied by extracellular deposits is calculated with respect to the total area of the entorhinal cortex.

The number of β-amyloid –positive cell clusters was quantified in the caudal portion of the hippocampus using the optical fractionation method.

Object recognition test

The efficacy of compound XVI in rescuing the behavioural deficits in AD11 mice was analysed using the object recognition test. The analysis consists of evaluating the ability of discriminating between a new object and a familiar one (Bartus, RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163, 495-529, 2000). AD11 mice show a progressive decrease of this ability of distinguishing new objects from old ones (Capsoni, S, Ugolini, G, Comparini, A, Ruberti, F, Berardi, N & Cattaneo, A. Alzheimer-like neurodegeneration in antinerve growth factor transgenic mice. *Proc Natl Acad Sci USA* 97, 6826-6831, 2000).

Before starting the trial, 6 and 12 month old mice were treated with compound XVI for 15 days in a dose of 15/mg/kg/day per os. The controls were age-matched non transgenic mice and transgenic AD11 mice treated with water and the same percentage of ethanol (2%).

5 The cognitive deficit was also induced in a group of 2-month non transgenic mice by subcutaneous administration of 0.5 mg/kg of scopolamine, a muscarinic receptor antagonist (Weiss B, Heller A. Methodological problems in evaluating the role of cholinergic mechanisms in behavior. Fed Proc 28, 135-146, 1969). A second group of animals received compound XVI (per os, 15 mg/kg) 20 min.
10 before scopolamine injection. A third group of non transgenic mice was formed by non-treated non transgenic mice.

The efficacy of Galantamine in rescuing the behavioural deficit in AD11 mice was analysed after oral administration of 3.5 mg/kg/day starting from 2 months of age until 6 months of age.

15 To carry out the experiment, the mice were placed in a box made of Plexiglas (60 cm x 60 cm x 60 cm). The walls and the floor of the box were covered with opaque, washable material. The box and objects used in this test were also washable. The box and objects were cleaned up between trials to stop build-up of olfactory cues. The mice received 3 sessions of 10 min duration in the empty box to
20 allow them to become familiar with the apparatus. During the test, each mouse was put back in the box and exposed to two identical objects (object A1 and A2, for example 2 cubes 12 cm wide) for 10 minutes. The experimenter measured the total time spent exploring each of the two objects. Then the mouse was returned to its cage. During an interval of 1 minute, 1 hour and 24 hours, the objects were removed from the box and one of the two was replaced by its identical copy (A3), while the other was replaced with a completely new object (object B). After a delay of 1 min., 1 hour and 24 hours the mouse was put back in the box and exposed to

the familiar object A3 and to the new object B for 10 min. The objects were placed in the same locations as the previous ones. The experimenter again measured the total time spent exploring each of the two objects. Exploration time is operationally defined as the time during which the mouse directly attended towards the object 5 with its head, at a distance not greater than 2 cm from the object. The discrimination index was calculated using the formula (N-F / N + F), where N is the time spent exploring the new object, and F the time spent exploring the familiar object.

Results

10 (a) Efficacy in blocking cholinergic deficit, tau phosphorylation and β-amyloid aggregation in aged AD11 mice after oral administration

Neurodegeneration in AD11 mice worsens with age and is fully blown at 15 months of age. At this age, the following can be seen in the brain of AD11 mice: neuronal death, cholinergic deficit (Melchiorre, C, Andrisano, V, Bolognesi, ML, 15 Budriesi, R, Cavalli, A, Cavrini, V, Rosini, M, Tumiatti, V & Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. *J Med Chem* 41, 4186-4189, 1998; Selkoe, DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 81, 741-766, 2001), presence of extracellular β-amyloid plaques (Inestrosa, NC, Alvarez A, 20 Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. *Neuron* 16, 881-91, 1996), dystrophic neurites and intracellular tangles composed of the hyperphosphorylated form of tau protein.
25 The compound XVI was administered per os in a dose of 7 mg/kg/day for 1 month to AD11 mice aged 15 months (n = 6, n is the number of mice used). The treatment determined an improvement in the number of cholinergic neurons in the basal

forebrain (figure 9).

The intracellular accumulation of hyperphosphorylated tau decreased in the mice treated with the compound XVI (figure 10C) in comparison with placebo-treated mice (figure 10B). The number of the cells containing phosphorylated tau in the somatodendritic compartment was approximately the same as that of age-matched non transgenic mice (figure 10A).

5 The administration of the compound XVI determined a decrease in the number of β-amyloid plaques in AD11 mice (figure 11C) in comparison with placebo-treated mice (figure 11B). Although the number of plaques did not reach the level that can be observed in age-matched non transgenic mice (figure 11A), the morphology of 10 plaques was different from the one observed in placebo-treated mice: the number of cells associated with plaques in mice treated with the compound XVI (figure 11C) was lower than that in placebo-treated mice (figure 11B).

In conclusion the results described demonstrate that: the compound XVI is active even after oral administration and that the compound XVI is able to improve 15 neurodegeneration also in aged mice in which the pathology is fully blown and in an advanced stage.

(b) Effects of the Compound XVI on behavioural deficits in AD11 mice and in mice treated with scopolamine

20 The efficacy of the compound XVI in treating behavioural deficit in AD11 mice was analysed using the object recognition test. The analysis consists of the evaluation of the ability to discriminate between new and familiar objects (Bartus, RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. 25 *Exp Neurol* 163, 495-529, 2000). AD11 mice show a progressive decrease in this ability to distinguish new objects from those already explored (Selkoe, DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 81, 741-766, 2001).

The administration of the compound XVI (15 mg/kg/day per os) allowed an improvement of the deficit in AD11 mice at 6 months (n = 10, figure 12) and 12 months (n = 8; figure 13) of age.

The same test was applied to non transgenic mice treated with the compound XVI
5 20 minutes before the administration of scopolamine. The mice treated with the compound XVI did not show any signs of amnesia and were able to distinguish the familiar objects from the new ones (figure 14).

In conclusion, the compound XVI is able to ameliorate the cognitive deficit determined by NGF deprivation in transgenic mice and by administering
10 scopolamine in non transgenic mice.

(c) Effects of the administration of the compound XVI to AD11 mice compared with the effects of other AChE inhibitors

The compound XVI, Galantamine and Tacrine were administered daily to AD11 mice. The drugs were administered per os (compound XVI and Galantamine) or via
15 intraperitoneal injection (compound XVI, Galantamine and Tacrine). They were administered starting from 1.5 months of age until 2 months of age. Treatment with the compound XVI and with Galantamine prevented the decrease of the number of cholinergic neurons in the basal forebrain, while Tacrine aggravated the cholinergic deficit (figure 15)

20 The compound XVI, Galantamine and Caproctamine were also administered to AD11 mice from 6 months of age for 15 days. While the compound XVI and Galantamine were able to rescue the cholinergic deficit in the basal forebrain, Caproctamine had no effect on the number of cholinergic neurons (figure 16).

After treatment with the compound XVI for 15 days, starting at 1.5 months of age
25 or 6 months of age, the compound XVI reduced the number of neurons labelled with antibodies against phospho-tau (figures 17 and 18). Galantamine (figures 17 and 18) and Caproctamine (figure 18) were ineffective.

In 6 month-old AD11 mice, the administration of the compound XVI and Galantamine reduced the extracellular deposition of APP, while Caproctamine was ineffective (figure 19).

The treatment with the compound XVI, starting at 6 months of age, was able to 5 reduce the number of cells accumulating β -amyloid protein in the hippocampus of AD11 mice. The same result is obtained using Galantamine, while Caproctamine was ineffective (figure 20).

The administration of the compound XVI for 2 weeks from 6 months of age determined a marked amelioration of the behavioural deficit, as occurred also with 10 Galantamine (figure 21)

In conclusion, the compound XVI is as effective as Galantamine, but superior to it in reverting the aspect of neurodegeneration linked with tau hyperphosphorylation. Caproctamine was ineffective against all aspects of Alzheimer neurodegeneration.

Note also that in the enclosed figures the data marked “**” present $P < 0.05$.

15 **Example 56**

The antioxidant power of XVI was tested, expressed as the ability to capture oxygen radicals, using the kit of Randox Laboratories® Ltd (UK) (Total antioxidant status) [Rice-Evans C. and Miller N.J. Total antioxidant status in plasma and body fluids, Methods Enzymol. 234 (1994) 279-293], after suitable experimental 20 modification.

The method used to assess the ability to neutralise free radicals is a colorimetric method. It is based on the reactivity of a peroxidase compound, methmyoglobin (6.1 μ M) ($HXFe^{3+}$) which, in the presence of hydrogen peroxide (250 μ M) in an aqueous buffer with physiological pH, stimulates the formation of 25 oxygen radicals, which it complexes in the form of ferrimyoglobin ($^*X-[Fe^{4+}=O]$). Ferrimyoglobin subtracts an electron from a cation (ABTS®) (2,2'-azino-di-[3-ethylbenzthiazoline sulphonate]) (610 μ M), returning to a methmyoglobin and

transforming ABTS[®] into coloured radical, detectable at 600 nm.

The capturing of free oxygen radicals by an antioxidant present in a solution reduces the formation of the coloured species and the corresponding absorbance to 600 nm at fixed times.

5 As reference antioxidant, able to inhibit the chromogenic reaction in a manner depending on concentration, a water-soluble derivative of Vitamin E was used, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).

10 The white is composed of phosphate buffer (80 mM, pH 7.4) methmyoglobin and ABTS[®] incubated at 37°C, the reference contains in addition Trolox while the sample contains in addition the compound XVI. The substratum H₂O₂ was added in each test and the absorbance was read at 600 nm at fixed times (t_0 and after 3 min.). The percentage colour loss of the white can be used as an indication of the antioxidant activity of the sample tested.

$$\% \text{ inhibition} = \Delta \text{Abs}_{\text{white}} - \Delta \text{Abs}_{\text{test}} / \Delta \text{Abs}_{\text{white}} \times 100$$

15 The following data were obtained:

	concentration [μM]	% inhibition*
Trolox	27	57.6±0.9
XVI	170	44.1±3.7

* Mean of two independent measurements, repeated in triplicate

The modification of the method shown concerns the addition of human serum albumin (25 μM) in the sample containing the compound XVI to assist its solubilisation and its respective white.

20 In the system described, the compound XVI demonstrated an antioxidant activity (capture of free radicals) because it inhibited the formation of the coloured radical species. The antioxidant power of the compound XVI is about 6 times lower than Trolox. However it must be stressed that the compound XVI was tested in the oxidated quinonic form, which in vivo in contact with the enzymatic reducing

- 56 -


systems, can be transformed into the more active hydroquinonic reduced form.

CLAIMS

1.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula

(I):

(I)



5

wherein R₁ represents a substituent chosen from the group consisting of:

- a hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group of from one to five carbon atoms, and
- a substituent having an attractor electron inductive effect;

10

R₂ and R₃ each independently of the other, represent a hydrogen or a saturated or unsaturated, linear or ramified alkylic group presenting from one to five carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

15

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group presenting from one to five carbon atoms,
- OMe, and
- SMe;

X represents a radical chosen from the group consisting of::

20

- -HC=CH-,
- -HC=N-,
- -S-,
- -O-, and

- -NH-;

T represents a saturated or unsaturated, linear or ramified alkylic group presenting from one to four carbon atoms;

Z represents a saturated or unsaturated, linear or ramified alkylic group
5 presenting from two to thirteen carbon atoms.

2.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) according to claim 1, wherein R₁ represents a substituent chosen from the group consisting of:

10 - a hydrogen,
- a substituent having an attractor electron inductive effect.

3.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) according to claim 1, wherein R₁ represents a substituent chosen from the group consisting of:

15 - a hydrogen,
- a halogen,
- NO₂, and
- MeO;

R₂ and R₃, each independently of the other, represent a hydrogen or a saturated or unsaturated, linear or ramified alkylic group presenting from one to
20 four carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group of from one to five carbon atoms,

25 T represents a saturated or unsaturated, linear or ramified alkylic group presenting from one to three carbon atoms;

Z represents a saturated or unsaturated, linear or ramified alkylic group

presenting from two to twelve carbon atoms.

4.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) according to claim 1, wherein R₁ represents a substituent chosen from the group consisting of:

5 - a hydrogen,
 - a halogen,
 - MeO;

R₂ and R₃, each independently of the other, represent a hydrogen or a saturated or unsaturated, linear or ramified alkylic group presenting from one to 10 two carbon atoms; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of:

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group of from one to four carbon atoms,

15 X represents the radical -HC=CH- or the radical -O-;

T represents the radical -CH₂-; and

Z represents a saturated or unsaturated, linear or ramified alkylic group presenting from two to seven carbon atoms.

5.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula 20 (I) according to claim 3, R₃ represents a hydrogen; R₄ and R₅, each independently of the other, represent a substituent chosen from the group consisting of::

- hydrogen,
- a saturated or unsaturated, linear or ramified alkylic group of from one to five carbon atoms,
- a ramified alkylic group of from three to four carbon atoms,

25 Z represents a saturated linear alkylic group presenting from two to seven carbon atoms.

6.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula (I) according to one of the claims from 1 to 4, wherein R₁ is in position 2 with respect to T.

7.- 2,5-bis-diamine-[1,4]benzoquinonic derivative having a general formula 5 (I) according to one of the claims from 1 to 5, wherein Z represents a saturated linear alkylic group presenting from two to seven carbon atoms.

8.- 2,5-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XVI).

9.- 2,5-Bis-{3-[ethyl-(2-methoxy-benzyl)-amino]-propylamino}-[1,4]benzoquinone (XII).

10. 10.- 2,5-Bis-[6-(benzyl-ethyl-amino)-hexylamino]-[1,4]benzoquinone (XVII).

11.- 2,5-Bis-{6-[ethyl-(3-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XXXIII).

12.- 2,5-Bis-{6-[ethyl-(4-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone (XXXVII).

13.- 2,5-Bis-{2-[ethyl-(2-methoxy-benzyl)-amino]-ethylamino}-[1,4]benzoquinone (XLV).

14.- 2,5-Bis-{7-[ethyl-(2-methoxy-benzyl)-amino]-heptylamino}-[1,4]benzoquinone (IL).

20 15.- 2,5-Bis-{6-[(2-methoxy-benzyl)-methylamino]-hexylamino}-[1,4]-benzoquinone (LIV).

16.- 2,5-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexylamino}-3,6-dimethyl-[1,4]-benzoquinone (LV).

25 17.- 2,5-Bis-[6-(2-methoxy-benzylamino)-hexylamino]-[1,4]-benzoquinone (LI).

18.- 2,5-Bis-[6-(ethyl-furan-2-ilmethyl-amino)-hexylamino]-[1,4]benzoquinone (XLI).

19.- 2,5-Bis-{6-[ethyl-(2-nitro-benzyl)-amino]-hexylamino}-
[1,4]benzoquinone (XXIX).

20.- 2,5-Bis-{6-[ethyl-(2-chloro-benzyl)-amino]-hexylamino}-
[1,4]benzoquinone (XVIII).

5 21.- 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one of the
claims from 1 to 19, for use as a medicament.


22.- 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one of the
claims from 1 to 20, for the treatment of Alzheimer's disease in mammals.

10 23.- Pharmaceutical preparation characterised in that it comprises a 2,5-bis-
diamine-[1,4]benzoquinonic derivative according to one of the claims from 1 to 20,
or one of its pharmaceutically acceptable salts and a pharmaceutically acceptable
excipient and/or diluant.

15 24.- Method for preparing a 2,5-bis-diamine-[1,4]benzoquinonic derivative
according to one of the claims from 1 to 20; the method comprising a nucleophile
substitution phase, in which on a p-benzoquinone having a general formula (VIII):

(VIII)

a substitution is made with a first intermediate compound having a general
formula (VII):



(VII)




20 in order to obtain the 2,5-bis-diamine-[1,4]benzoquinonic derivative having a

general formula (I).

25.- Method according to claim 24, and comprising a hydrolysis phase, in which a second intermediate compound having a general formula (VI):


(VI),



5 in which D represents a Bn or another protective group that is substantially stable in a basic environment, is hydrolysed in order to obtain said first intermediate compound having a general formula (VII).

26.- Method according to claim 25, and comprising an addition phase, in which a third intermediate compound having a general formula (IV):

10 (IV)



is made to react in the presence of a base with a compound having a general formula (V):


(V)

$(R_2)_f A,$

15 in which A is an attractor electron group, and f is 1 or 2 in order to obtain said second intermediate compound having a general formula (VI).

27.- Method according to claim 26, and comprising a second addition phase, in which a protected (amino-alkyl)-carbamic acid having a general formula (II):

(II),



20 is added to a compound having a general formula (III):



(III),

in which E represents a residue chosen from the group consisting of:

- =O,
- -Cl,
- 5 - -Br, or
- -I;

in order to obtain said third intermediate compound having a general formula (IV); with the condition that where E represents =O the method comprises a reduction phase in order to obtain said third intermediate compound having a
10 general formula (IV).

28.- Intermediate compound having a general formula (VII) according to
claim 24.
29.- Compound having a general formula (VI) according to claim 25.
30.- Compound having a general formula (IV) according to claim 24.
15 31.- Use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one
of the claims from 1 to 20, for the production of a pharmaceutical preparation for
the treatment of Alzheimer's disease in mammals.

32.- Use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one
of the claims from 1 to 20, for the production of a pharmaceutical preparation for
20 the treatment of pathologies characterised by deposits of β -amyloid protein (A β) in
mammals.

33.- Use of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one
of the claims from 1 to 20, for the production of a pharmaceutical preparation for
the treatment of degenerative pathologies of the nervous system in mammals.

25 34.- Method for the treatment of Alzheimer's disease in a mammal; the

method comprises the administration to said mammal of an efficacious quantity of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one of the claims from 1 to 20.

35.- Method for the treatment of the disease of a pathology characterised by 5 deposits of β -amyloid protein ($A\beta$) in a mammal; the method comprises the administration to said mammal of an efficacious quantity of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one of the claims from 1 to 20.

36.- Method for the treatment of degenerative pathologies of the nervous system in a mammal; the method comprises the administration to said mammal of 10 an efficacious quantity of a 2,5-bis-diamine-[1,4]benzoquinonic derivative according to one of the claims from 1 to 20.

1 / 6




Fig.1




Fig.2




Fig.3




Fig.4

2 / 6




Fig.5




Fig.6




Fig.7




Fig.8

3 / 6




Fig.9




Fig.10



Fig.11

4 / 6




Fig.12




Fig.13




Fig.14

5 / 6

Fig.16




Fig.15




Fig.17






Fig.18



6 / 6



■ AD11 + XVI


□ AD11 + placebo

□ AD11 + GAL (3.5 mg/kg i.p.)

■ AD11 + XVI

□ AD11 + placebo

□ AD11 + GAL (3.5 mg/kg i.p.)



■ AD11 + XVI


□ AD11 + placebo

□ AD11 + GAL (3.5 mg/kg i.p.)

■ AD11 + XVI

□ AD11 + placebo

□ AD11 + GAL (3.5 mg/kg i.p.)



■ AD11 + XVI

□ AD11 + placebo

□ AD11 + GAL (3.5 mg/kg os)

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07C225/28 C07C221/00 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 20040 A (EASTMAN KODAK CO) 14 October 1993 (1993-10-14) claim 1 ----- X	1,2,5,7, 24,28
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 11, 29 November 1996 (1996-11-29) & JP 8 193026 A (TEIJIN LTD), 30 July 1996 (1996-07-30) abstract -----	1-36

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the International search

23 July 2003

Date of mailing of the International search report

30/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Janus, S.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 34–36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9320040	A	14-10-1993	US	5189088 A		23-02-1993
			AT	154590 T		15-07-1997
			CA	2131534 A1		14-10-1993
			DE	69311709 D1		24-07-1997
			DE	69311709 T2		30-10-1997
			EP	0633876 A1		18-01-1995
			JP	7508710 T		28-09-1995
			WO	9320040 A1		14-10-1993
JP 8193026	A	30-07-1996	NONE			